<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04848246</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-898/DUHS/Approval/2017/136</org_study_id>
    <nct_id>NCT04848246</nct_id>
  </id_info>
  <brief_title>Effect of Smoking Cessation on Tuberculosis Treatment Outcomes</brief_title>
  <official_title>Efficacy of Smoking Cessation Interventions on Tuberculosis Treatment Outcomes Among Newly Diagnosed Pulmonary Tuberculosis Patients; a Single Blind Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dow University of Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dow University of Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was a Randomized Controlled Trial conducted at Ojha Institute of Chest Diseases,&#xD;
      Dow University of Health Sciences, Karachi, among pulmonary tuberculosis patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 6, 2017</start_date>
  <completion_date type="Actual">October 15, 2019</completion_date>
  <primary_completion_date type="Actual">September 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A total of three groups, two intervention and one control</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Outcome assessor for tuberculosis outcomes at the study site were blinded in terms of intervention allocation</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients completing anti-tuberculosis treatment</measure>
    <time_frame>six months</time_frame>
    <description>Among both smear positive and smear negative TB patients, successful completion of ATT will be labeled at the end of 6 months period if the patients has been compliant with ATT through six months period..</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving abstinence from smoking</measure>
    <time_frame>six months</time_frame>
    <description>Abstinence is defined as staying away from smoking and it will be assessed at week 1, week 4, week 12 and week 24 will be assessed in following two ways:&#xD;
i. Self-reported abstinence using questionnaire ii. Expired carbon monoxide (eCO) levels using Micro Smokerlyzer (Bedfont Scientific) of less than 7 ppm.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of patients defaulting anti-tuberculosis treatment.</measure>
    <time_frame>Six Months</time_frame>
    <description>Treatment default will be defined as interruption of anti-tuberculosis treatment for â‰¥2 consecutive months. This outcome will be assessed in both smear positive and smear negative patients.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">292</enrollment>
  <condition>Tuberculosis, Pulmonary</condition>
  <arm_group>
    <arm_group_label>Bupropion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Behavioural Change Communication</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion</intervention_name>
    <description>This group received Bupropion 150 mg twice daily for 10 weeks</description>
    <arm_group_label>Bupropion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioural Change Communication</intervention_name>
    <description>This group will receive Behavioural Change Communication</description>
    <arm_group_label>Behavioural Change Communication</arm_group_label>
    <arm_group_label>Bupropion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  pulmonary tuberculosis patients of age 18 years or above&#xD;
&#xD;
          -  registered under Directly Observed Treatment Short course (DOTS) at Ojha Institute of&#xD;
             Chest Diseases&#xD;
&#xD;
          -  reported to have smoked 100 plus cigarettes in past and currently smoking cigarettes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Extra pulmonary tuberculosis&#xD;
&#xD;
          -  drug resistant tuberculosis&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  positive history of epilepsy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muhammad Tahir Rizwan Khan, M.Phil.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dow University of Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dow University of Health Sciences</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 4, 2021</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dow University of Health Sciences</investigator_affiliation>
    <investigator_full_name>Muhammad Tahir Rizwan Khan</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>smoking cessation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

